Central Line Catheters Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Central Line Catheters Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Fairfield Market Research, a prominent source of market intelligence, has released an insightful report on the Central Line Catheters market, forecasting substantial expansion in the industry. In 2024, the global central line catheters market is expected to generate revenue of US$ 2.9 billion. The market is projected to reach a significant size of US$ 5 billion by the end of 2031.

Role and Applications of Central Line Catheters

Central line catheters are thin, flexible tubes used extensively across healthcare units, including hemodialysis units, critical care departments, and oncology units. They play a vital role in various applications such as rapid fluid resuscitation, drug administration, parenteral nutrition, and hemodialysis. These catheters come in diverse sizes, types, and sites and can sometimes lead to complications. Central line catheter kits, encompassing triple-lumen, double-lumen, and large bore single-lumen catheters, are indispensable for enhancing the care of critically ill patients. They are employed for delivering multiple medications, continuous infusion chemotherapy, parenteral nutrition, and vesicant drug administration.

Key Market Insights:
• Peripherally inserted central catheters (PICCs) held a substantial market share of 37.8% in 2022.
• Revenue from central line catheters constituted 4.9% of the global catheters market in 2022.

The central line catheter is favored for vesicant drug administration due to its larger bore size and heparin requirements. The subclavian vein is preferred over the femoral vein due to its lower infection rate, making it a safer option.

Central line catheters can be non-tunneled for easy insertion in emergent situations, including emergency hemodialysis, cardiac catheterization, vascular access in unstable patients, transvenous pacemaker placement, and large-volume fluid administration. They are also used in non-emergent scenarios like total parenteral nutrition and routine blood draws, which require hypertonic saline solutions, potassium, or calcium chloride in large quantities.

A Common Procedure in Healthcare Settings

Central line catheterization is a common procedure performed on approximately 8% of all hospitalized patients, as per a research article published in Frontiers - Medicine 2022. It is employed for various purposes, including medication delivery, extended intravenous therapy, challenging peripheral venous access, monitoring, and specific treatments. Patients undergoing central line catheterization during hospital stays necessitate proper care, including routine insertion checks, daily monitoring, and adherence to clinical governance requirements. Effective monitoring ensures the maintenance of central venous pressure, oxygen saturation, and fluid resuscitation.

Benefits for Manufacturers and Healthcare Providers

Rising Prevalence of Chronic Illnesses: Central line catheters are integral in the management of chronic diseases such as cancer, kidney failure, and cardiovascular disorders. The increasing prevalence of these conditions drives the demand for central line catheters. The trend of hospital consolidation leads to larger healthcare systems and higher patient volumes, enabling hospitals to negotiate better pricing and volume discounts for medical devices, including central line catheters.

Development of Antimicrobial Catheters: Several manufacturers are introducing innovative product lines, including antimicrobial-coated catheters, to gain a competitive edge. These catheters inhibit the growth of bacteria, reducing the risk of catheter-related bloodstream infections (CRBSIs). Antimicrobial agents such as silver, chlorhexidine, or minocycline are incorporated into the catheter surface, potentially significantly reducing infection risks.

Barriers to Adoption of Central Line Catheters

Device Dysfunction and Complications: Device dysfunction is a significant concern, as malfunctions or failures of central line catheter devices can have serious implications for patient safety and treatment outcomes. Device-related complications can include infections, blockages, or improper fluid or medication administration. These incidents erode patient trust and can result in legal consequences for manufacturers. Stringent quality and safety standards, along with increasing compliance requirements, pose challenges to manufacturers.

Product Recalls: Product recalls represent a significant hindrance, as they require manufacturers to absorb replacement costs, reimbursement costs, legal costs, and more, leading to substantial financial losses. Recent examples include the FDA's Class I recall of over 260,000 Teleflex catheter systems in June 2023 due to catheter separation and leakage concerns.

Patient Safety Concerns: Central line insertions carry a risk of complications, and errors during the procedure can lead to adverse events. Cardiac complications, infections, and device dysfunction are among the concerns that impact patient safety.

Country-wise Insights

Profitable Market in the United States: The United States, with its high volume of surgical procedures, growing cancer and infectious disease cases, and advanced healthcare infrastructure, accounted for a substantial 39.7% share of the global central line catheters market in 2022. The rising number of hospital admissions further propels demand for central line catheters in the country.

Growing Adoption in China: China, with its increasing adoption of cancer therapeutics and active participation from healthcare services, held a 6.3% share of the global market in 2022. The use of peripherally inserted central catheters (PICCs) is prominent in China for the treatment of leukemia, boosting the demand for catheters.

Widespread Use of Ultrasound Guidance in Germany: Germany accounted for 4.8% of the global market in 2022. The country has implemented advanced ultrasound guidance (UG) for central line catheterization, with UG being considered a cost-saving strategy. The effectiveness of UG in avoiding surgical complications makes it a preferred method.

Competition Landscape

Key players in the central line catheters market are adopting diverse strategies to bolster their global presence and enhance their business operations.

Key Companies Covered:
• Becton, Dickinson and Company
• Teleflex Incorporated
• B. Braun Melsungen AG
• AngioDynamics, Inc.
• Medtronic Plc.
• Smiths Medical (ICU Medical Inc.)
• Cook Group
• Vygon S.A.
• Argon Medical Devices, Inc.
• KIMAL PLC
• Lepu Medical Technology (Beijing) Co., Ltd. (Comed B.V.)
• Merit Medical Systems, Inc.
• Fresenius Medical Care AG & Co. KGaA
• Medical Components, Inc.
• Integer Holdings Corporation
• Biomerics
• Heka S.R.L.

Key Segments of Central Line Catheters Industry Research

Product:
• Peripherally Inserted Central Catheters (PICCs)
• Implanted Ports
• Tunneled Central Venous Catheters
• Non-tunneled Central Venous Catheters

Design:
• Single Lumen
• Double Lumen
• Multiple Lumen

Property:
• Antimicrobial Catheters
• Non-antimicrobial Catheters

Composition:
• Polyurethane
• Teflon
• Silicone Rubber

End User:
• Hospitals
• Ambulatory Surgical Centers
• Specialized Clinics
• Cancer Research Institutes

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.